Global Prostate Cancer Therapeutics Market Reaches USD 22.2 Bn in 2026, Driven by Rising Disease Prevalence and Advancements in Targeted Therapies

Technological Innovations, Increasing Treatment Adoption, and Expanding Drug Pipelines to Drive Global Prostate Cancer Therapeutics Market to USD 29.3 Bn by 2033 at 8.1% CAGR – Coherent Market Insights

The Global Prostate Cancer Therapeutics Market, by drug type (Hormonal Therapy, Anti-androgens, Immunotherapy, Targeted Therapy, and Chemotherapy) and by distribution channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies) was valued at USD 22.2 Bn in 2026 and is projected to exhibit a CAGR of 8.1% over the forecast period (2026–2033). 

Prostate cancer remains a major public-health and socioeconomic burden among men. According to the American Cancer Society’s Cancer Facts & Figures 2026, approximately 333,830 new prostate cancer cases are expected to be diagnosed in the U.S. in 2026, while around 36,320 men are projected to die from the disease. The incidence rate is also nearly 70% higher among Black men than White men. Advanced prostate cancer may extend to the seminal vesicles, nearby pelvic tissues and lymph nodes, while distant metastatic disease commonly affects the bones, adrenal glands, liver, and lungs. The substantial disease burden and continuing need for effective treatments for advanced and metastatic cancer are expected to support growth of the prostate cancer therapeutics market.

Research, clinical development, biomarker testing, and regulatory approval of targeted therapies are also transforming the market. For instance, in June 12 2026, the U.S. Food and Drug Administration approved AstraZeneca’s Truqap (capivasertib) in combination with abiraterone and prednisone for adults with PTEN-deficient metastatic androgen pathway modulation-naïve or sensitive prostate cancer. The FDA simultaneously approved Roche’s VENTANA PTEN assay as a companion diagnostic. In the 1,012-patient CAPItello-281 trial, the combination produced median radiographic progression-free survival of 33.2 months, compared with 25.7 months for the control regimen.

Furthermore, in February 2026, Astellas Pharma and Vir Biotechnology entered a global strategic collaboration to develop and commercialize VIR-5500, an investigational PSMA-targeting dual-masked T-cell engager for metastatic prostate cancer. These developments demonstrate the market’s shift toward biomarker-directed therapies, companion diagnostics, targeted combinations, and next-generation immunotherapies.

Browse 29 Market Data Tables and 33 Figures spread through 160 Pages and in-depth TOC on "Prostate Cancer Therapeutics Market, by Drug Type (Hormonal Therapy, Anti-androgens, Immunotherapy, Targeted Therapy, and Chemotherapy) and By Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies) - Global Forecast to 2033".

To know the latest trends and insights prevalent in the prostate cancer therapeutics market, click the link below:

https://www.coherentmarketinsights.com/market-insight/prostate-cancer-therapeutics-market-1257

Market Opportunity

• Expansion of Biomarker-Guided Precision Therapies

The growing identification of actionable genetic and molecular alterations creates significant opportunities for targeted prostate cancer treatments and companion diagnostic tests. For instance, in June 2026, the U.S. FDA approved AstraZeneca’s Truqap (capivasertib) in combination with abiraterone and prednisone for adults with PTEN-deficient metastatic hormone-sensitive prostate cancer. The approval was supported by Phase III data showing a 19% reduction in the risk of radiographic disease progression or death. This development is expected to increase demand for PTEN testing and biomarker-guided treatment selection.

• Development of Bispecific T-Cell-Engaging Therapies

Novel immunotherapies targeting prostate-specific proteins offer opportunities for patients with advanced disease who have exhausted existing treatments. For instance, in February 2026, Johnson & Johnson reported promising early antitumor activity from pasritamig combined with docetaxel in metastatic castration-resistant prostate cancer. Pasritamig is an investigational bispecific antibody targeting KLK2 on prostate cancer cells and CD3 on T cells. This approach could establish a new treatment class and expand therapeutic options beyond androgen receptor inhibitors, chemotherapy, and radioligand therapy. (Source: Johnson & Johnson)

• Expansion into Earlier-Stage and High-Risk Disease

The substantial patient population creates opportunities to develop therapies for localized high-risk, biochemical recurrent, and hormone-sensitive prostate cancer. The U.S. SEER program estimates approximately 333,830 new prostate cancer cases and 36,320 deaths in 2026. During the first quarter of 2026, Amgen reported ongoing studies of xaluritamig in newly diagnosed localized intermediate- or high-risk disease, biochemical recurrence, and metastatic hormone-sensitive prostate cancer. Successful expansion into these earlier settings could significantly increase the eligible treatment population and duration of therapy. (Source: Amgen Inc.)

Market Trends

• Development of Next-Generation PSMA T-Cell Engagers

Next-generation PSMA-directed immunotherapies are attracting substantial partnerships and investment. In February 2026, Astellas and Vir Biotechnology formed a global collaboration to develop VIR-5500, an investigational dual-masked PSMA/CD3 T-cell engager for advanced metastatic prostate cancer. Its masking technology is designed to activate primarily within the tumor microenvironment and limit off-target effects. Vir received USD 335 million in upfront and near-term payments, demonstrating strong commercial interest in immune-based modalities.

• PARP–ARPI Combinations Moving into Earlier Treatment Settings

PARP inhibitor and androgen receptor pathway inhibitor combinations are moving into earlier disease stages. In May 2026, Pfizer reported Phase 3 TALAPRO-3 results for talazoparib plus enzalutamide in HRR gene-altered metastatic castration-sensitive prostate cancer. The combination reduced the risk of radiographic progression or death by 52%, while estimated three-year progression-free survival was 77% versus 56%. These findings strengthen demand for routine HRR and BRCA testing. (Source: Pfizer)

• Earlier Use of PSMA-Targeted Radioligand Therapy

PSMA-targeted radioligand therapy is expanding from heavily treated disease toward hormone-sensitive prostate cancer. In May 2026, Novartis reported that adding Pluvicto to androgen receptor pathway inhibition and androgen deprivation therapy reduced the risk of PSA progression by 58% in the PSMAddition study. Deeper PSA responses were maintained through 48 weeks. Novartis subsequently filed regulatory submissions in the U.S., China, and Japan for this earlier treatment setting. (Source: Novartis)

• Adaptive and Response-Guided Radioligand Dosing

Adaptive dosing is emerging to improve radioligand treatment efficiency and patient quality of life. On July 16, 2026, Telix and St Vincent’s Hospital dosed the first patients in the Phase 2 OPTIMAL-e trial of investigational TLX597-Tx for metastatic hormone-sensitive prostate cancer. The study uses PSMA-PET imaging and PSA measurements to continue, pause, or restart treatment according to response, potentially reducing unnecessary exposure while preserving disease control. (Source: Astella Global)

• Rapid Commercial Growth of Radioligand Therapies

Commercial adoption of targeted radioligand therapy is accelerating as treatment indications and geographic access expand. Novartis reported Pluvicto sales of USD 642 million in Q1 2026, representing 70% constant-currency growth. The company attributed this performance to strong U.S. demand in the pre-taxane metastatic castration-resistant setting and expanding access outside the U.S. This momentum indicates growing physician acceptance, payer coverage, treatment-center capacity, and patient access to specialized prostate cancer radiopharmaceuticals.

• Combining Radiopharmaceuticals with Standard Systemic Therapies

Radiopharmaceuticals are increasingly being combined with established systemic treatments instead of being reserved as standalone later-line therapies. In July 2026, Telix reported FDA protocol alignment for the Phase 3 ProstACT Global study of investigational TLX591-Tx in metastatic castration-resistant prostate cancer. The therapy is designed for two doses administered 14 days apart alongside abiraterone, enzalutamide, or docetaxel. The randomized expansion targets approximately 490 patients, although U.S. initiation remains subject to FDA review. (Source: Telix Pharmaceuticals)

Key Development

• In February 2026, the U.K. Medicines and Healthcare products Regulatory Agency authorized Novartis’ Pluvicto for PSMA-positive metastatic castration-resistant prostate cancer after androgen receptor pathway inhibitor therapy, where delaying taxane chemotherapy is considered appropriate. The expanded indication enables eligible patients to receive PSMA-targeted radioligand therapy earlier and supports growing demand for PSMA testing, nuclear-medicine infrastructure, and radiopharmaceutical treatment capacity. (Source: Novartis Pharmaceuticals UK Ltd)

• In June 2026, the U.S. FDA approved AstraZeneca’s Truqap (capivasertib) in combination with abiraterone and prednisone for adults with PTEN-deficient metastatic androgen pathway modulation-naïve or sensitive prostate cancer. Based on the Phase III CAPItello-281 study, the combination reduced the risk of radiographic disease progression or death by 19%. It is the first FDA-approved targeted treatment specifically addressing PTEN-deficient disease in this treatment setting. (Source: AstraZeneca)

Key takeaways of the Prostate Cancer Therapeutics Market

• The global prostate cancer therapeutics market is expected to expand at a CAGR of 8.1% during the forecast period (2026–2033) as there exists a largely untapped and highly lucrative market especially in Asia Pacific, Latin America, Middle East and Africa.
• Hormone Therapy is widely preferred, as it helps to shrink the prostate and any cancer that has spread, and makes the treatment more effective
• Hospital Pharmacies is the major distribution channel of prostate cancer therapeutics that drives the growth owing to it being the primary care center for prostate cancer
• Some of the major players involved in global prostate cancer therapeutics market are Johnson & Johnson, Astella, Inc, Sanofi-Aventis, Bayer AG, AstraZeneca Plc, Pfizer Inc., Dendreon Corporation (Sanpower Group Co. Ltd.), Ipsen Group, Tolmar Pharmaceuticals Inc, Endo Pharmaceuticals, AbbVie, Inc.